Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients

Critères d'éligibilité

Inclusion Criteria (patients): • Informed Consent as documented by signature; • HADS total score of 6 or greater; • Age 18 years or older; • Progressive cancer diagnosis (estimated life expectancy 24 months or more) • Able to attend study visits; • Ability to speak and understand German; Exclusion Criteria (patients): • Clinician assessed cognitive impairment; • Clinician assessed alcohol or drug abuse; • Pregnancy or breast-feeding; • Severe hypertension (greater than 200/120 mmHg); • Anamnestic mood disorder (major depressive disorder, treatment resistant depression, etc.); • Suicidality (C-SSRS total score of "low" or less); • Weight less than 39 kg, greater than 170 kg; • Angina pectoris or myocardial infarction in the last 6 months; • Lifetime abuse or dependence on ketamine or phencyclidine; • Substance abuse or dependence in the 6 months before screen; • Nasal obstructions or history of nasal surgery. • Serious health risk caused by increased blood pressure or intracranial pressure: • Known aneurysmal vascular disease (including intracranial, thoracic or abdominal aortic or peripheral arterial vessels); • Known history of intracerebral hemorrhage; • Recent (within 6 weeks) cardiovascular event including myocardial infarction (MI). Inclusion criteria (caregivers): • Informed Consent as documented by signature; • Age 18 years or older; • Able to attend study visits; • Ability to speak and understand German. Exclusion criteria (caregivers): \- None.